Trends in oral anticoagulant prescription in patients with nonvalvular atrial fibrillation in Flanders and the impact of switching patients from vitamin K antagonists to DOACS in terms of the burden caused by complications of the disease: a registry-based study

References

• January CT, Samuel Wann L, Calkins H, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation. J Am Coll Cardiol. 2019;74(1):104–132.
   PubMed Web of Science ®Google Scholar
• Kakkar AK, Mueller I, Bassand JP, et al. International longitudinal registry of patients with atrial fibrillation at risk of stroke: global anticoagulant registry in the FIELD (GARFIELD). Am Heart J. 2012;163(1):13–19.e1.
   PubMed Web of Science ®Google Scholar
• Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37:2893–2962.
   PubMed Web of Science ®Google Scholar
• De Souza Lima Bitar Y, Neto MG, Lima Filho JA, et al. Comparison of the new oral anticoagulants and warfarin in patients with atrial fibrillation and valvular heart disease: systematic review and meta-analysis. Drugs R D. 2019;19:117–126.
   PubMed Web of Science ®Google Scholar
• Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomized trials. Lancet. 2014;383:955–962.
   PubMed Web of Science ®Google Scholar
• Kleintjens J, Li X, Simoens S, et al. Cost-effectiveness of rivaroxaban versus warfarin for stroke prevention in atrial fibrillation in the Belgian healthcare setting. PharmacoEconomics. 2013;31:909–918.
   PubMed Web of Science ®Google Scholar
• Wouters H, Thijs V, Annemans L. Cost-effectiveness of dabigatran etexilate in the prevention of stroke and systemic embolism in patients with atrial fibrillation in Belgium. J Med Econ. 2013;16(3):407–414.
   PubMedGoogle Scholar
• Haas S, Camm AJ, Bassand JP, et al. Predictors of NOAC versus VKA use for stroke prevention in patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF. Am Heart J. 2019;213:35–46.
   PubMed Web of Science ®Google Scholar
• Lip GYH, Laroche C, Popescu MI, et al. Improved outcomes with European society of cardiology guideline-adherent antithrombotic treatment in high-risk patients with atrial fibrillation: a report from the EORP-AF general pilot registry. Europace. 2015;17:1777–1786.
   PubMed Web of Science ®Google Scholar
• Van Brabandt H, San Miguel L, Fairon N, et al. Anticoagulants in non-valvular atrial fibrillation. Immunological Reviews. 2017;279:36.
   PubMedGoogle Scholar
• Réunion de consensus: usage rationnel des anticoagulants oraux en cas de fibrillation auriculaire et en cas de thromboembolie veineuse. INAMI, 2017.
   Google Scholar
• Johnson CO, Nguyen M, Roth GA. GBD 2016 Stroke Collaborators. Global, regional and national burden of stroke, 1990-2016: a systematic analysis for the global burden of disease study 2016. Lancet Neurol. 2019;18:439–458.
   PubMed Web of Science ®Google Scholar
• Truyers C, Goderis G, Dewitte H, et al. The Intego database: background, methods and basic results of a Flemish general practice-based continuous morbidity registration project. BMC Medical Informatics and Decision Making. 2014;14. 10.1186/1472-6947-14-48.
   PubMed Web of Science ®Google Scholar
• Feigin VL, Stark BA, Johnson CO; GBD 2019. Stroke collaborators. “Global, regional, and national burden of stroke and its risk factors, 1990–2019: a systematic analysis for the global burden of disease study 2019”. Lancet Neurol. 2021;20:795–820.
   PubMed Web of Science ®Google Scholar
• Caldeira, Caldeira D, Nunes-Ferreira A, et al. Non-vitamin K antagonist oral anticoagulants in elderly patients with atrial fibrillation: a systematic review with meta-analysis and trial sequential analysis. Arch Gerontol Geriatr. 2019;81:209–214.
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in Patients with Atrial fibrillation. N Engl J Med. 2011;364(9):806–817.
   PubMed Web of Science ®Google Scholar
• Truyers C, Goderis G, Dewitte H, et al. The Intego database background, methods and basic results of a Flemish general practice-based continuous morbidity registration project. BMC Med Inform Decis Mak. 2014;14:48. 10.1186/1472-6947-14-48
   PubMed Web of Science ®Google Scholar
• Bartholomeeusen S, Kim CY, Mertens R, et al. The denominator in general practice, a new approach from the Intego database. Fam Pract. 2005;22:442–447.
   PubMed Web of Science ®Google Scholar
• Lippi, G., Sanchis-Gomar, F. and Cervellin, G. Global epidemiology of atrial fibrillation: an increasing epidemic and public health challenge. Int J Stroke. 2019. DOI:10.1177/1747493019897870. journals.sagepub.com/home/wso
   Web of Science ®Google Scholar
• Di Carlo, A., Bellino, L., Consoli, D., Mori, F., Zaninelli, A., Baldereschi, M., Cattarinussi, A., D’Alfonso, M.G., Gradia, C., Sgherzi, B. and Pracucci, G. Prevalence of atrial fibrillation in the Italian elderly population and projections from 2020 to 2060 for Italy and the European Union: the FAI Project. Eur Soc Cardiol. 2019. DOI:10.1093/europace/euz141.
   Google Scholar
• Vitolo, Vitolo M, Proietti M, et al. The Euro Heart Survey and EURObservational Research Programme (EORP) in atrial fibrillation registries: contribution to epidemiology, clinical management and therapy of atrial fibrillation patients over the last 20 years. Intern Emerg Med. 2020;15:1183–1192.
   PubMed Web of Science ®Google Scholar
• Cools, F., Wollaert, B., Vervoort, G. Treatment patterns in anticoagulant therapy in patients with newly diagnosed atrial fibrillation in Belgium: results from the GARFIELD-AF registry. Acta Cardiol. 2018. DOI:10.1080/00015385.2018.1494089.
   Web of Science ®Google Scholar
• Adderley, N.J. Ryan, R., Nirantharakumar, K. and Marshall, T. Prevalence and treatment of atrial fibrillation in UK general practice from 2000 to 2016. Arrythmias Sudden Death. 2018. DOI:10.1136/heartjnl-2018-312977.
   Google Scholar
• Kozieł, M., Teutsch, C., Halperin, J.L. Atrial fibrillation and comorbidities: clinical characteristics and antithrombotic treatment in GLORIA-AF. Plos One. 2021. DOI:10.1371/journal.pone.0249524.
   Web of Science ®Google Scholar
• Boriani, G., Proietti, M., Laroche, C. Changes to oral anticoagulant therapy and risk of death over a 3-year follow-up of a contemporary cohort of European patients with atrial fibrillation final report of the EURObservational Research Programme on Atrial Fibrillation (EORP-AF) pilot general registry. Int J Cardiol. 2018. https://www.internationaljournalofcardiology.com/article/S0167-5273(17)38059-2/fulltext
   Web of Science ®Google Scholar
• Wafa, H.A., Wolfe, C.D., Emmett, E, Roth, G.A., Johnson, C.O. and Wang, Y. 2020. Burden of Stroke in Europe. Stroke. https://www.ahajournals.org/doi/suppl/10.1161/STROKEAHA.120.029606
   Google Scholar
• Korelitz, Korelitz BI, Sommers SC, et al. Responses to drug therapy in ulcerative colitis. Evaluation by rectal biopsy and histopathological changes. The American Journal of Gastroenterology. 1975;64(5):365–370.
   PubMed Web of Science ®Google Scholar
• Devleesschauwer, Devleesschauwer B, McDonald SA, et al. Valuing the years of life lost due to COVID-19: the differences and pitfalls. Int J Public Health. 2020;65(6):719–720.
   PubMed Web of Science ®Google Scholar